All stock lists
Unlock the score
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
Healthcare · Biotechnology
0.76-0.05 (-5.85%)
Insider Score
/ 100
MGX Insider Score
Metagenomi Therapeutics, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
MGX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | -257.00 K | 1.25 M | 3.91 M | 8.66 M | 8.51 M | 4.13 M |
| Revenue Growth (YoY) | -103.02 % | -69.76 % | -59.32 % | -24.80 % | -57.45 % | -63.02 % |
| Cost of Revenue | 0.00 | 863.00 K | 1.30 M | 1.32 M | 22.51 M | 25.14 M |
| Gross Profit | -257.00 K | 385.00 K | 2.61 M | 7.33 M | -13.99 M | -21.02 M |
| SG&A Expense | 6.00 M | 6.54 M | 5.48 M | 6.21 M | 6.99 M | 6.80 M |
| R&D Expense | 22.51 M | 19.30 M | 21.50 M | 23.96 M | 22.51 M | 25.14 M |
| Operating Expenses | 28.52 M | 24.97 M | 26.98 M | 30.17 M | 6.99 M | 6.80 M |
| Operating Income | -28.77 M | -24.59 M | -24.37 M | -22.84 M | -20.99 M | -27.82 M |
| Pretax Income | -27.48 M | -23.05 M | -22.49 M | -20.63 M | -19.86 M | -24.94 M |
| Tax Provision | 0.00 | -10.00 K | 34.00 K | -234.00 K | 44.00 K | 98.00 K |
| Net Income | -27.48 M | -23.06 M | -22.53 M | -20.39 M | -19.91 M | -25.04 M |
| EPS (Basic) | -0.73 | -0.61 | -0.60 | -0.55 | -0.54 | -0.68 |
| EPS (Diluted) | -0.73 | -0.61 | -0.60 | -0.55 | -0.54 | -0.68 |
| Shares Outstanding | 37.66 M | 37.58 M | 37.62 M | 37.35 M | 37.16 M | 37.02 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.